0000939767-18-000106.txt : 20180524 0000939767-18-000106.hdr.sgml : 20180524 20180524202456 ACCESSION NUMBER: 0000939767-18-000106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180522 FILED AS OF DATE: 20180524 DATE AS OF CHANGE: 20180524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLSEY LANCE CENTRAL INDEX KEY: 0001202106 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 18859442 MAIL ADDRESS: STREET 1: C/O EXELIXIS INC STREET 2: 170 HARBOR WAY CITY: SAN FRANCISCO STATE: CA ZIP: 94083 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 BUSINESS ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 210 E. GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 4 1 wf-form4_152720783720964.xml FORM 4 X0306 4 2018-05-22 0 0000939767 EXELIXIS, INC. EXEL 0001202106 WILLSEY LANCE C/O EXELIXIS, INC. 210 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2018-05-22 4 S 0 50000 21.40 D 418273 D Option (right to buy) 20.5 2018-05-24 4 A 0 31167 0 A 2018-05-24 2025-05-23 Common Stock 31167.0 31167 D Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.26 to $21.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. /s/ Jennifer Drimmer Rokovich, Attorney in Fact 2018-05-24